Primus In News
Indian pharma ramps up US acquisitions amid regulatory and market shifts
15-03-2025
Nilaya Varma, CEO & Co-Founder, Primus Partners, and Vivek Tandon, Vice President, Primus Partners, share their view on the expansion of Indian pharmaceutical companies in the US through strategic acquisitions. They highlight Sun Pharma’s $355 million acquisition of Checkpoint Therapeutics as a key move to bolster its oncology and immunotherapy portfolio.
Explore Related Insights
- How this Pune-based startup is using drones to make confined-space industrial inspections safer
- IndiGo, SpiceJet stocks could see some turbulence in near-term, say analysts; here are key levels for investors
- Bitcoin Soars After Trump’s Win: What Regulatory Changes the Crypto Industry Can Expect
- Budget 2024 highlights: Basic duty cut on seafood, capital gains tax changes and more
